Valuation: Sernova

Market Cap 49.09M 34.6M 30.28M 27.9M 25.86M 3.28B 49.88M 335M 130M 1.62B 130M 127M 5.6B P/E 2026 *
-4.33x
P/E 2027 * -3.25x
Enterprise Value 49.09M 34.6M 30.28M 27.9M 25.86M 3.28B 49.88M 335M 130M 1.62B 130M 127M 5.6B EV / Sales 2026 *
-
EV / Sales 2027 * 9.82x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 week-3.70%
Current month-3.70%
1 month-13.33%
3 months-21.21%
6 months-7.14%
1 week 0.13
Extreme 0.13
0.14
1 month 0.12
Extreme 0.12
0.17
3 years 0.12
Extreme 0.12
1.03
5 years 0.12
Extreme 0.12
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 2024-08-11
Director of Finance/CFO 60 2024-10-10
Investor Relations Contact - 2024-10-10
Director TitleAgeSince
Director/Board Member 55 -
Chairman 75 2025-09-22
Director/Board Member 60 2012-04-18
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%0.00%-18.75%-86.60% 35.86M
+1.54%+4.73%-15.99%+12.05% 124B
+0.48%+4.68%+2.93%-1.89% 12.79B
+1.31%+7.79%+48.48%+117.61% 8.73B
-4.70%-1.16%-49.44%-73.07% 4.06B
-4.42%+2.41%+21.94%+43.47% 2.78B
-4.51%-2.27%-12.01%-16.99% 1.88B
-2.17%+0.42%-4.12%-27.70% 1.65B
-1.47%+23.29%-22.71%-60.30% 1.49B
Average -1.74%+4.21%-5.52%-10.38% 19.73B
Weighted average by Cap. +1.04%+4.51%-10.98%+13.65%

Financials

2026 *2027 *
Net sales - 5M 3.52M 3.08M 2.84M 2.63M 334M 5.08M 34.07M 13.25M 165M 13.23M 12.94M 570M
Net income -12.83M -9.04M -7.91M -7.29M -6.76M -858M -13.03M -87.41M -33.99M -423M -33.94M -33.2M -1.46B -19.77M -13.93M -12.19M -11.24M -10.42M -1.32B -20.09M -135M -52.4M -653M -52.31M -51.18M -2.26B
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
26-07-07 $0.1300 -3.70%
26-07-06 $0.1350 +3.85%
26-07-03 $0.1300 0.00%
26-07-02 $0.1300 -3.70%
26-06-30 $0.1350 0.00%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1300CAD
Average target price
0.4500CAD
Spread / Average Target
+246.15%

Quarterly revenue - Rate of surprise